Page 73 - Demo

CUAJ %u2022 FEBRUARY 2025 %u2022 VOLUME 19, ISSUE 2 71Focal therapy to treat prostate cancer9. National Institute for Health and Care Excellence. Irreversible electroporation for treating prostate cancer. [Online July 5, 2023]. https://www.nice.org.uk/guidance/ipg768/chapter/1-Recommendations. Accessed January 22, 2024.10. Parker JL, Muhammad Q, Kedzierski J, et al. The interplay between regulation and design in medical wearable technology. Wear Tech Med Health Care 2018:291-305. https://doi.org/10.1016/B978-0-12-811810-8.00015-411. US Food and Drug Administration: Overview of medical device regulation: Regulatory controls. [Online]. Available at: https://www.fda.gov/medical-devices/overview-deviceregulation/regulatory-controls. Accessed October 3, 202412. De novo classification request for Sonablate%u00ae 450. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/reviews/den150011.pdf. Accessed October 3, 202413. Ablatherm 510(k). [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf15/k153023.pdf. Accessed October 3, 202414. Ablatherm Fusion 510(k). [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172285.pdf. Accessed October 3, 202415. Cryocare 2010. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K101333.pdf. Accessed October 3, 202416. Cryocare 2015. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/K141110.pdf. Accessed October 3, 202417. Cryocare 2020. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201588.pdf. Accessed October 3, 202418. Cryosuccess 2009. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf9/K091721.pdf. Accessed October 3, 202419. CryoTouch 2009. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf12/K120415.pdf. Accessed October 3, 202420. ERBE Cryo 2015. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf15/K151041.pdf. Accessed October 3, 202421. Exablate 2021. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf21/K212150.pdf. Accessed October 3, 202422. Focal One 2018. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172721.pdf. Accessed October 3, 202423. IRE 2015. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf15/K150089.pdf. Accessed October 3, 202424. IRE 2019. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183385.pdf. Accessed October 3, 202425. FLA 2020. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201687.pdf. Accessed October 3, 202426. RFA 1998. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf/K981672.pdf. Accessed October 3, 202427. TULSA 2019. [Online]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191200.pdf.28. TULSA 2022. [Online] K211858 Trade/Device Name: TULSA-PRO%u00ae System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211858.pdf. Accessed October 3, 202429. Uniblate 2007. [Online] Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf7/K070101.pdf. Accessed October 3, 202430. Bilbro NA, Hirst A, Paez A, et al. The IDEAL reporting guidelines: A Delphi consensus statement stage specific recommendations for reporting the evaluation of surgical innovation. Ann Surg 2021;273:82-5. https://doi.org/10.1097/SLA.000000000000418031. Zhang K, Stricker P, L%u00f6hr M, et al. A multicenter international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer Prostatic Dis 2024;27:525-30. https://doi.org/10.1038/s41391-023-00783-y32. Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int 2023;13:6-13. https://doi.org/10.1111/bju.1594633. Cribbs KA, Manning EF, Zhou J, et al. Real-world comparative safety and effectiveness of irreversible electroporation and high-intensity focused ultrasound for prostate cancer ablation. Urology 2023;174:7-17. https://doi.org/10.1016/j.urology.2023.01.02434. Li H, Xu Z, Lv Z, et al. Survival after cryotherapy versus radiotherapy in low and intermediate risk localized prostate cancer. Clin Genitourin Cancer 2023;21:679-93. https://doi.org/10.1016/j.clgc.2023.06.00935. Rompr%u00e9-Brodeur A, Marcq G, Tholomier C, et al. Role of systematic control biopsies following partial gland ablation with high-intensity focused ultrasound for clinically significant prostate cancer. J Urol 2021;206:1177-83. https://doi.org/10.1097/JU.000000000000193436. Klotz L, Pavlovich CP, Chin J et al. Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 5-year follow up [abstract]. Urol Oncol-Semin Ori 2024; 42:S83. https://doi.org/10.1016/j.urolonc.2024.01.23437. van Riel LAMJG, Geboers B, Kabaktepe E, et al. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int2022;130:611-8. https://doi.org/10.1111/bju.1575938. Dosanjh A, Harvey P, Baldwin S, et al. High-intensity focused ultrasound for the treatment of prostate cancer: A national cohort study focusing on the development of stricture and fistulae. Eur Urol Focus 2021;7:340-6. https://doi.org/10.1016/j.euf.2019.11.01439. Ghoreifi A, Kaneko M, Peretsman S, et al. Patient-reported satisfaction and regret following focal therapy for prostate cancer: A prospective multicenter evaluation. Eur Urol Open Sci2023;50:10-6. https://doi.org/10.1016/j.euros.2023.02.00340. Chin JL, Donnelly BJ, Nair SM, et al. The history of cryosurgery in Canada: A tale of two cities. Can Urol Assoc J 2020;14:299-304. https://doi.org/10.5489/cuaj.662541. Siddiqui K, Chopra R, Vedula S, et al. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology 2010;76:1506-11. https://doi.org/10.1016/j.urology.2010.04.04642. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009;182:1371-7. https://doi.org/10.1016/j.juro.2009.06.03543. Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: Validation of focal therapy and imaging accuracy. Eur Urol 2010;57:1111-4. https://doi.org/10.1016/j.eururo.2010.03.00844. Azzouzi AR, Lebdai S, Benzaghou F, et al. Vascular-targeted photodynamic therapy with TOOKAD%u00ae Soluble in localized prostate cancer: Standardization of the procedure. World J Urol 2015;33:937-44. https://doi.org/10.1007/s00345-015-1535-245. Siddiqui K, Chopra R, Vedula S, et al. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: Initial studies. Urology 2010;76:1506-11. https://doi.org/10.1016/j.urology.2010.04.04646. Ghai S, Finelli A, Corr K, et al. MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: Early results of a phase 2 trial. Radiology2021;298:695-703. https://doi.org/10.1148/radiol.202120271747. Chin JL, Billia M, Relle J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: A prospective Phase 1 Clinical Trial. Eur Urol 2016;70:447-55. https://doi.org/10.1016/j.eururo.2015.12.02948. Ghai S, Finelli A, Corr K, et al. MRI-guided focused ultrasound focal therapy for intermediate-risk prostate cancer: Final results from a 2-year phase 2 clinical trial. Radiology 2024;310:e231473. https://doi.org/10.1148/radiol.23147349. ClinicalTrials.gov. A comparison of TULSA procedure vs. radical prostatectomy in participants with localized prostate cancer (CAPTAIN). [Online] Available at: https://www.clinicaltrials.gov/study/NCT05027477. Accessed January 22, 2024.50. ClinicalTrials.gov. HDR Focal: Feasibility study. [Online] Available at: https://classic.clinicaltrials.gov/ct2/show/results/NCT02918253?view=results. Accessed January 22, 2024.51. ClinicalTrials.gov. MRI-guided focal laser ablation of prostate cancer (MRgFLA). [Online] Available at: https://clinicaltrials.gov/study/NCT03650595. Accessed August 4, 2024.52. Clinicaltrials.gov. PSMA-guided ablation of the prostate (P-GAP). [Online] Available at: https://clinicaltrials.gov/study/NCT06003556. Accessed August 4, 2024.53. ClinicalTrials.gov. A Pan-Canadian, investigator initiated clinical trial with focal IRE directed to intermediate-risk prostate cancer (WIRED). [Online] Available at: https://clinicaltrials.gov/study/NCT06451445. Accessed August 4, 2024.54. ClinicalTrials.gov. Pivotal study of the NanoKnife system for the ablation of prostate tissue (PRESERVE). [Online] Available at: https://clinicaltrials.gov/study/NCT04972097. Accessed January 22, 2024.55. George AK, Miocinovic R, Patel AR, et al. A description and safety overview of irreversible electroporation for prostate tissue ablation in intermediate-risk prostate cancer patients: Preliminary results from the PRESERVE Trial. Cancers 2024;16:2178. https://doi.org/10.3390/cancers1612217856. Dixon CM, Levin RM, Cantrill CH, et al. Transurethral vapor ablation in patients with intermediate-risk localized prostate cancer. J Endourol 2023;37:225-32. https://doi.org/10.1089/end.2022.045257. ClinicalTrials.gov. Water vapor ablation for localized intermediate-risk prostate Cancer (VAPOR 2). [Online] Available at: https://clinicaltrials.gov/study/NCT05683691?term=NCT05683691&rank=1. Accessed January 22, 2024.58. Rastinehad AR, Anastos H, Wajswol E, et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc Natl Acad Sci U S A2019;116:18590-96. https://doi.org/10.1073/pnas.190692911659. Wang X, Tsui B, Ramamurthy G, et al. Theranostic agents for photodynamic therapy of prostate cancer by targeting prostate-specific membrane antigen. Mol Cancer Ther2016;15:1834-44. https://doi.org/10.1158/1535-7163.MCT-15-0722